MKI67 and lung adenocarcinoma: Interestingly, we observed an increase in Ki-67+ DNT cells in approximately 57% (29/51) of late-stage NSCLC patients following the first cycle of anti-PD-1 treatment, and these proliferating DNT cells exhibited effector-like phenotypes and enhanced cytotoxicity towards the lung adenocarcinoma cell line A549.